FAQ’S

Diagnostic Research Laboratory - FAQ'S December 2022

Biobank - Oncology Samples

How many oncology samples are in the biobank and from what geographic regions?

More than 10 000 samples Geographic regions are EU (Poland, Ukraine, Lithuanian, Bulgaria) , North and South America (USA, Brazil), Africa, India

What tumor indications and disease mutations, histologies, or drivers are represented?

All solid tumors and hematology tumors. Biospecimens with specific molecular characteristics could be offered which include tumors and plasma from specimens with or without KRAS, EGFR, BRAF mutations, HER2 amplification, and overexpression.

Have the oncology samples been profiled for RNA/DNA/protein analysis? If so, what methodology have been used?

Where available, molecular profiling of biospecimens will be provided. (Sergiy whenever any tissue is obtained, it will be important to request all available information cellular and molecular diagnostics. Also clinical information including patient age, sex, primary site of occurrence, grade and clinical stage (size, nodal involvement & metastasis).

What material (eg, frozen tissue, extracted DNA or protein or RNA) can be shipped from DRL to the investigative site?
We offer laboratory service including preparation of blood fractions (plasma, serum, buffy coat, PBMC), isolation of viable cells from fresh dissociated tissues (including tumor-infiltrating lymphocytes from fresh tumors), isolation of DNA and RNA. Biospecimens may be offered in several formats including fresh tissue, fresh frozen (FF) tissue, formalin fixed paraffin embedded (FFPE) tissue, or tissues otherwise preserved as requested and biofluids (peripheral blood, plasma, serum, saliva, sputum, urine, bone marrow aspirate, amniotic fluid, etc.).

We provide access to a diverse range of donors with a full medical and drug history. Our database contains more than 50,000 well-characterized cases, including 100,000 images of the tumor.
Can DRL perform custom in-house analysis of the oncology samples? If so, what services can be performed

We can provide immunohistochemical staining (IHC) of fresh frozen tissues and and formalin fixed paraffin embedded tissues, flow cytometry of cells including blood isolated cells, and detached tumor cells. We can provide Histopathology and NGS

Are there unique aspects of DRL’s samples, methodology, etc, that differentiate from competitors?
  • Extensive experience in the biobank sector
  • Large network of human biospecimen collection from more than 30 sites, from several different countries.
  • Access a diverse range of donors with a full-medical and drug history
  • We can offer material that are procured by standard or customized protocols
Are there unique aspects of DRL’s samples, methodology, etc, that differentiate from competitors?

We can provide samples from North and South America hospital, Various European countries, Asia and Africa.

Biobank - Organoid models

How many organoid models are available and what tumor types are represented (in terms of indication, disease mutations, histology, or drivers?

DRL is currently developing organoid models derived from different cancers. Please inquire for specific information. These will include, colon, gastric, prostate, breast, ovarian, pancreatic, brain, bone and tumors originating from various organs that include liver, kidney, lungs, skeletal and smooth muscle.

What characterization has been performed on organoid models (eg, genome sequencing, mutation analysis, etc )?

 Sergiy and Alberto, it is too early to have this section as we don’t have the infrastructure for such analysis. Yes, it is true, we can outsource this to outside vendors but it should be upon client request as it can be quite expensive.

Can custom analysis be performed at DRL with organoid models? If so, which analyses can be performed (eg, in vitro pharmacology, RNA or protein analysis)?

Custom analysis can ne performed upon request. (Again once we know what the client

Can organoids be shipped to investigative sites?

Organoids can be shipped to investigative sites. Typically the organoids will be shipped as multiple organoid samples per cryovials. Where possible, due to geographical location, organoids may be shipped as a suspension culture for seeding in matrix.

How many times can organoids be passaged? Are there proprietary culture conditions?

I need to investigate this. One would expect that the tumor organoids would have a perpetual life and can be passaged indefinitely. However, I would not say this as you will get customers who will ask for refunds when the organoids do not propagate due to their inexperience/bad practice. At this stage, there are no proprietary culture conditions. However, we should be able to develop novel medium for sale, once we have the project up and going.

Can investigative sites request that specific organoid models be developed (eg, KRAS mutant colorectal cancer)?

Customers/Clients can request specific organoid models to be developed. Sergiy Alberto I would not specify any further, let the customer/client request.

Have in house pharmacologic data been generated on organoid platform (eg, testing small molecules or antibodies)?

It is too early to have this question. However, further in the future, we should be able to have our own in-house characterization of the organoid models and we should be able to reference papers/data from previous customers who had purchased the model and published papers in which the purchased organoids had been used.

Are there unique aspects of DRL’s organoid platform that differentiate from competitors?

Too early to have this section. Hopefully we should be able to offer organoid models from patient’s  pre radio/chemotherapy and recurrent tumors post radio/chemotherapy. Or we should be able to derive and offer organoids derived from primary cancers and metastatic cancers.

Have organoids been implanted into mice for in vivo pharmacology studies? Yes

Sergiy/Alberto, this is the intention. We intend to derive organoids directly from tumor biopsies  and then test them for growth in immune compromised mice/rats. Conversely, we will also be able to grow patient tumors first xenografts then isolate and purify the cancer cells using selection markers and then growing these purified cells as organoids. 

Does DRL have GLP certification?

DRL is currently developing and implementing GLP facilities. Please inquire.

Other Services

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.